Zur Kurzanzeige

dc.creatorNtaios, G.en
dc.creatorPapavasileiou, V.en
dc.creatorDiener, H. C.en
dc.creatorMakaritsis, K.en
dc.creatorMichel, P.en
dc.date.accessioned2015-11-23T10:41:28Z
dc.date.available2015-11-23T10:41:28Z
dc.date.issued2012
dc.identifier10.1161/strokeaha.112.673558
dc.identifier.issn0039-2499
dc.identifier.urihttp://hdl.handle.net/11615/31438
dc.description.abstractBackground and Purpose-To assess whether the combined analysis of all phase III trials of nonvitamin-K-antagonist (non-VKA) oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack shows a significant difference in efficacy or safety compared with warfarin. Methods-We searched PubMed until May 31, 2012, for randomized clinical trials using the following search items: atrial fibrillation, anticoagulation, warfarin, and previous stroke or transient ischemic attack. Studies had to be phase III trials in atrial fibrillation patients comparing warfarin with a non-VKA currently on the market or with the intention to be brought to the market in North America or Europe. Analysis was performed on intention-to-treat basis. A fixed-effects model was used as more appropriate than a random-effects model when combining a small number of studies. Results-Among 47 potentially eligible articles, 3 were included in the meta-analysis. In 14 527 patients, non-VKAs were associated with a significant reduction of stroke/systemic embolism (odds ratios, 0.85 [95% CI, 074-0.99]; relative risk reduction, 14%; absolute risk reduction, 0.7%; number needed to treat, 134 over 1.8-2.0 years) compared with warfarin. Non-VKAs were also associated with a significant reduction of major bleeding compared with warfarin (odds ratios, 0.86 [ 95% CI, 075-0.99]; relative risk reduction, 13%; absolute risk reduction, 0.8%; number needed to treat, 125), mainly driven by the significant reduction of hemorrhagic stroke (odds ratios, 0.44 [95% CI, 032-0.62]; relative risk reduction, 57.9%; absolute risk reduction, 0.7%; number needed to treat, 139). Conclusions-In the context of the significant limitations of combining the results of disparate trials of different agents, non-VKAs seem to be associated with a significant reduction in rates of stroke or systemic embolism, hemorrhagic stroke, and major bleeding when compared with warfarin in patients with previous stroke or transient ischemic attack. (Stroke. 2012; 43: 3298-3304.)en
dc.source.uri<Go to ISI>://WOS:000311497600034
dc.subjectanticoagulantsen
dc.subjectapixabanen
dc.subjectatrial fibrillationen
dc.subjectdabigatranen
dc.subjectrivaroxabanen
dc.subjectstrokeen
dc.subjecttransient ischemic attacken
dc.subjectwarfarinen
dc.subjectCOST-EFFECTIVENESSen
dc.subjectDABIGATRAN ETEXILATEen
dc.subjectSUBGROUP ANALYSISen
dc.subjectWARFARINen
dc.subjectPREVENTIONen
dc.subjectTHROMBOEMBOLISMen
dc.subjectRIVAROXABANen
dc.subjectAPIXABANen
dc.subjectEMBOLISMen
dc.subjectAFen
dc.subjectClinical Neurologyen
dc.subjectPeripheral Vascular Diseaseen
dc.titleNonvitamin-K-Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack A Systematic Review and Meta-Analysis of Randomized Controlled Trialsen
dc.typejournalArticleen


Dateien zu dieser Ressource

DateienGrößeFormatAnzeige

Zu diesem Dokument gibt es keine Dateien.

Das Dokument erscheint in:

Zur Kurzanzeige